Victory Capital Management Inc. Purchases 11,216 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Victory Capital Management Inc. boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 11.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 113,630 shares of the company’s stock after purchasing an additional 11,216 shares during the period. Victory Capital Management Inc.’s holdings in Elanco Animal Health were worth $1,376,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Atria Investments Inc raised its holdings in shares of Elanco Animal Health by 57.9% during the 3rd quarter. Atria Investments Inc now owns 56,613 shares of the company’s stock worth $832,000 after buying an additional 20,760 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in Elanco Animal Health by 81.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 33,193 shares of the company’s stock worth $488,000 after acquiring an additional 14,902 shares in the last quarter. AMG National Trust Bank lifted its holdings in shares of Elanco Animal Health by 3.1% in the third quarter. AMG National Trust Bank now owns 133,738 shares of the company’s stock worth $1,965,000 after acquiring an additional 4,073 shares during the last quarter. Quest Partners LLC boosted its stake in shares of Elanco Animal Health by 915.1% in the 3rd quarter. Quest Partners LLC now owns 16,201 shares of the company’s stock valued at $238,000 after purchasing an additional 14,605 shares in the last quarter. Finally, Pathstone Holdings LLC grew its holdings in shares of Elanco Animal Health by 0.7% during the 3rd quarter. Pathstone Holdings LLC now owns 546,793 shares of the company’s stock valued at $8,032,000 after purchasing an additional 3,698 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ELAN. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lowered their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.17.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Up 1.6 %

Shares of ELAN opened at $10.82 on Wednesday. The stock’s 50-day moving average price is $11.41 and its two-hundred day moving average price is $12.67. Elanco Animal Health Incorporated has a 12 month low of $10.03 and a 12 month high of $18.80. The company has a market capitalization of $5.35 billion, a PE ratio of 27.04, a PEG ratio of 2.50 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business’s revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.